OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Haematology is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Towards reparatory measures: blood donation, health systems, and men who have sex with men	215
A new player in IDH1 mutated myeloid neoplasias	212
Pegcetacoplan: climbing up the complement cascade	181
Risk stratification for Down syndrome and acute lymphocytic leukaemia: one size does not fit all	170
Lines of the haematology community	150
Correction to Lancet Haematol 2025; 12: e109–19	139
Long-term neurodevelopmental outcomes in infants with haemolytic disease of the newborn treated with darbepoetin	138
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial	129
Epistemic limitations of measurable residual disease in haematological malignancies	129
Low-dose aspirin versus placebo in postpartum venous thromboembolism: a multi-national, pilot, randomised, placebo-controlled trial	111
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial	111
Allogeneic haematopoietic stem-cell transplantation versus gene therapy for haemoglobinopathies	110
Orla McCourt—making space for proactive rehabilitation in haematology	103
Making blood count	97
The value of teaching the influence of sex and gender on health outcomes	95
Further investment for cancer reduction in the USA	95
Mitapivat for treatment of pyruvate kinase deficiency	93
Reducing toxic waste: improving toxicity capture in childhood cancer	92
Have cancer, will travel	87
Using immunogenetics to inform immunotherapy of lymphoid malignancies	82
A century between pandemics and poisonings	79
Future role of topical pimecrolimus in early stage mycosis fungoides?	77
Haploidentical bone marrow transplantation for severe aplastic anaemia: looking to the future	76
Retinopathy associated with severe thrombocytopenia	76
Filling the data gaps on sickle cell anaemia in sub-Saharan Africa	76

Neutrophil-erythrocyte rosettes suggestive of Coombs-negative autoimmune haemolysis	69
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives	68
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study	68
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study	66
A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma	65
Haematology's role on the path to health for all Africans	65
A comprehensive approach to therapy of haematological malignancies in older patients	63
Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues	61
Packed red blood cell transfusion in preterm infants	61
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	60
Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?	59
Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study	58
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	58
Modelling the mortality of sickle cell disease in Africa	57
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China	56
All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial	55
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility	54
Consideration of ATG-free therapy with eltrombopag and cyclosporine for severe aplastic anaemia	53
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial	53
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations – Authors' reply	53
Vaccine efficacy and iron deficiency: an intertwined pair?	52
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial	51
Trends, opportunities, and challenges of clinical trials for haematological diseases in China	50
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial	50